Salipro Biotech
A privately-held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics.
The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro platform technology for the stabilization of membrane proteins.
Salipro has signed multiple research collaborations with top-tier pharma and biotech companies, and as of September 2023, has entered into a research collaboration with Japan's Sumitomo Pharma to reveal the mechanism of action and pharmacological characterization of a drug candidate.
Latest Salipro Biotech News & Features
12 September 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze